What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?

M Preusser; M Geurts; JA Hainfellner; MJ van den Bent

doi:10.1093/neuonc/noad113

What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?

M Preusser^*
, M Geurts
, JA Hainfellner
, MJ van den Bent

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Editorial › Academic › peer-review

7 Citations (Scopus)

Original language	English
Article number	noad113
Pages (from-to)	1915-1917
Number of pages	3
Journal	Neuro-Oncology
Volume	25
Issue number	11
Early online date	21 Jul 2023
DOIs	https://doi.org/10.1093/neuonc/noad113
Publication status	Published - 1 Nov 2023

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/neuonc/noad113

Cite this

@article{dbe540007bbb42699e6a581485031879,

title = "What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?",

author = "M Preusser and M Geurts and JA Hainfellner and \{van den Bent\}, MJ",

note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.",

year = "2023",

month = nov,

day = "1",

doi = "10.1093/neuonc/noad113",

language = "English",

volume = "25",

pages = "1915--1917",

journal = "Neuro-Oncology",

issn = "1522-8517",